<DOC>
	<DOCNO>NCT00229658</DOCNO>
	<brief_summary>This open label , observational study design collect data characterize use SYMLIN follow introduction medication marketplace . Health care provider subject select study participation intend representative provider prescribe , subject receive , SYMLIN therapy .</brief_summary>
	<brief_title>An Observational Study Evaluating SYMLINÂ® ( Pramlintide Acetate ) Injection Use Insulin Using Patients With Type 2 Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>The following inclusion criterion consistent information SYMLIN package insert apply insulin use patient type 2 type 1 diabetes : Have fail achieve desire optimal level glycemic control despite utilizing appropriate , individualized insulin regimen Have A1C &lt; =9.0 % within 3 month study enrollment Are receive ongoing diabetes care guidance Health Care Provider ( HCP ) train use SYMLIN The following exclusion criterion consistent SYMLIN package insert specifically exclude patient : Are poorly compliant current insulin regimen , define HCP Are poorly compliant prescribe blood glucose self monitoring , define HCP Have experience recurrent patientascertained severe hypoglycemia require assistance past 6 month Have hypoglycemia unawareness Have confirm diagnosis gastroparesis Require use drug stimulate gastrointestinal motility Are female pregnant lactate HCP determine potential benefit justify potential risk fetus infant Have treat SYMLIN within 3 month prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>pramlintide</keyword>
	<keyword>Symlin</keyword>
	<keyword>Amylin</keyword>
	<keyword>phase 4</keyword>
</DOC>